Genomic approaches in breast cancer research

Briefings in Functional Genomics

Volumn 12, Issue 5, 2013, Pages 391-396

  Donahue, Henry J ^a   Genetos, Damian C ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Genomics; Histology; Microarray; Tumor

Indexed keywords

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; GENE EXPRESSION; GENE TECHNOLOGY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; MICROARRAY ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; PHENOTYPE; PREDICTION;

BREAST CANCER; GENOMICS; HISTOLOGY; MICROARRAY; TUMOR;

BIOMEDICAL RESEARCH; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; NEOPLASM GRADING; SIGNAL TRANSDUCTION;

EID: 84884526059     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elt019     Document Type: Article

References (40)

1. Pusztai L, Mazouni C, Anderson K, et al. Molecular classification of breast cancer: limitations and potential. Oncologist 2006;11:868-77.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CACancerJ Clin 2011;61:69-90.
3. Cavallaro S, Paratore S, de Snoo F, et al. Genomic analysis: toward a new approach in breast cancer management. Crit Rev OncolHematol 2012;81:207-23.
4. Breasted JH. New York HS TheEdwinSmithSurgicalPapyrus. Chicago, IL: The University of Chicago press, 1930.
5. Mukherjee S. Emperor ofMaladies:ABiography ofCancer. New York: Simon & Schuster, 2010.
6. Ackerknecht EH. Historical notes on cancer. Med Hist 1958; 2: 114.
7. Papavramidou N, Papavramidis T, Demetriou T. Ancient Greek and Greco-Roman methods in modern surgical treatment of cancer. Ann Surg Oncol 2010;17:665.
8. MUSTACCHI P. Ramazzini and Rigoni-Stern on parity and breast cancer. Clinical impression and statistical corroboration. Arch InternMed 1961;108:639-42.
9. Olson JS. Bathsheba's Breast. Baltimore, MD: Johns Hopkins University Press, 2005.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-10.
11. Rakha E, Reis-Filho J, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 2010;12:207.
12. Elston CW, Gresham GA, Rao GS, et al. The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. BrJCancer 1982;45:655.
13. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
14. Stevens E, Kimler BF, Davis MK, et al. A newly proposed semi-automated method of grading invasive lobular carcinoma: a unifying concept and correlation with prognostic markers and patient survival. Ann Clin Lab Sci 2009;39: 25-31.
15. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378:1812-23.
16. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
17. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378: 789-92.
18. Zhang H, Tombline G, Weber BL. BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 1998;92: 433-6.
19. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-30.
20. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
21. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-74.
22. Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. ProcNatlAcad SciUSA 2003;100:8418-23.
23. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. ClinCancer Res 2005;11:5678-85.
24. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
25. Ivshina AV, George J, Senko O, etal. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006;66:10292-301.
26. Ma X-J, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;100:5974-9.
27. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. JClin Oncol 2007;25:1239-46.
28. Desmedt C, Giobbie-Hurder A, Neven P, et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMCMed Genomics 2009;2:40.
29. Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57.
30. Group EBCTC. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
31. Barnadas A, Estévez LG, Lluch-Hernández A, et al. An overview of letrozole in postmenopausal women with hormone- responsive breast cancer. Adv Therapy 2011;28: 1045-8.
32. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
33. Gatza ML, Lucas JE, Barry WT, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA 2010;107:6994-9.
34. Nielsen TO, Hsu FD, Jensen K, etal. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-74.
35. Gresham D, Dunham MJ, Botstein D. Comparing whole genomes using DNA microarrays. Nat Rev Genet 2008;9: 291-302.
36. Akavia UD, Litvin O, Kim J, et al. An integrated approach to uncover drivers of cancer. Cell 2010;143:1005-17.
37. Alderton GK. Genomics: driving cancer biology. Nat Rev Cancer 2011;11:79.
38. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basallike breast cancer metastasis and xenograft. Nature 2010;464: 999-1005.
39. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149:979-93.
40. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.